BHUDEV C DAS

Amity Institute of Molecular Medicine & Stem Cell Research, Noida

Bhudev C Das has made outstanding contributions in the field of cancer research, tumor virology, human genetics and mutation research. He has published more than 210 research papers in reputed international journals and distinguished himself as a renowned Molecular Oncologist. He has worked with the Nobel Laureate, Prof. Harald zur Hausen at German Cancer Research Centre (DFKZ), Heidelberg, and later he pioneered the work in India on Human Papillomavirus (HPV) that causes cervical and other cancers. He established National and WHO Regional HPV Referral Centre for South-East Asia at ICPO. His present areas of research are transcriptional regulation, miRNA regulation, cancer stem cell and cancer drug discovery. Das is the recipient of President’s gold medal of the Dr. B.C. Roy National Award of MCI, Sandoz Oration Award of ICMR, among several others, including the prestigious J.C. Bose National Fellowship (2008-2016). He is a Fellow of all four major national science and medical academies (FNA, FASc, FNASc and FAMS) and of the Union for International Cancer Control (UICC), Geneva. He was WHO expert advisor of the Global HPV LabNet & HPV Vaccine Program at Geneva for several years.

BHUDEV C DAS

SESSION 2C: Symposium: Community Health – A Genomic Perspective

Rajiva Raman, BHU, Varanasi

Public health genomics to innovative targeted therapeutic approaches for relapse-free survival of cancer patients

In this talk, the speaker will discuss the application of omics-based approaches in early detection, prevalence, progression, prevention and management of human health and disease. He will also broach the subject of Human Papillomaviruses (HPVs), specifically the high-risk HPV- 16 variant that was identified and employed to develop an indigenous therapeutic-cum-preventive chimeric-DNA vaccine construct for effective prevention and treatment of cervical cancer. He will also talk about a novel triple conjugate drug curcumin-folic acid-cancer drug (Doxorubicin) that was developed by his team for targeted delivery to cancer and cancer stem cells.

© 2018 Indian Academy of Sciences, Bengaluru.